Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: Role of TNF-α1

FASEB Journal

Volumn 20, Issue 6, 2006, Pages 670-682

  Sriram, Krishnan ^a   Matheson, Joanna M ^a   Benkovic, Stanley A ^a   Miller, Diane B ^a   Luster, Michael I ^a   O'Callaghan, James P ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Brain; Microglia; Neurodegeneration; Neuroinflammation; Neuroprotection

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1ALPHA; MICROTUBULE ASSOCIATED PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; NOMIFENSINE; THORIUM; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN REGION; CELL ACTIVATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; HIPPOCAMPUS; IMMUNOREACTIVITY; MALE; MICROGLIA; MOUSE; NERVE CELL LESION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BRAIN; C57BL MOUSE; CORPUS STRIATUM; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; INTOXICATION; METABOLISM; MOUSE MUTANT; PATHOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; CORPUS STRIATUM; CYTOKINES; DOPAMINE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; MPTP POISONING; NF-KAPPA B; NOMIFENSINE; OXIDATIVE STRESS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646255922     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.05-5106com     Document Type: Article

References (79)

1. Bauer, J., Strauss, S., Schreiter-Gasser, U., Ganter, U., Schlegel, P., Witt, I., Yolk, B., and Berger, M. (1991) Interleukin-6 and alpha-2- macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285, 111-114
2. Fillit, H., Ding, W. H., Buee, L., Kalman, J., Altstiel, L., Lawlor, B., and Wolf-Klein, G. (1991) Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129, 318-320
3. Merrill, J. E. (1992) Proinflammatory and anti-inflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome. J. Immunother. 12, 167-170
4. Boka, G., Anglade, P., Wallach, D., Javoy-Agid, F., Agid, Y., and Hirsch, E. C. (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172, 151-154
5. Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., and Nagatsu, T. (1994) Tumor necrosis factor-alpha increases both in brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165, 208-210
6. Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M., and Nagatsu, T. (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile Parkinsonism and Parkinson's disease. Neurosci. Lett. 211, 13-16
7. Raivich, G., Bluethmann, H., and Kreutzberg, G. W. (1996) Signaling molecules and neuroglial activation in the injured central nervous system. Keio J. Med. 45, 239-247
8. Ransohoff, R. M., Glabinski, A., and Tani, M. (1996) Chemokines in immune-mediated inflammation of the central nervous system. Cytokine Growth Factor Rev. 7, 35-46
9. Stoll, G., and Jander, S. (1999) The role of microglia and macrophages in the pathophysiology of the CNS. Prog. Neurobiol. 58, 233-247
10. Dickson, D. W., Lee, S. C., Mattiace, L. A., Yen, S. H., and Brosnan, C. (1993) Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7, 75-83
11. McGeer, P. L., and McGeer, E. G. (1998) Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis. Assoc. Disord. 12, S1-S6
12. Masliah, E., and LiCastro, F. (2000) Neuronal and synaptic loss, reactive gliosis, microglial response, and induction of the complement cascade in Alzheimer's disease. In Neurodegenerative dementias (Clark, C. M., and Trojanowski, J. Q., eds) pp. 131-146, McGraw-Hill, New York
13. Vila, M., Jackson-Lewis, V., Guegan, C., Wu, D. C., Teismann, P., Choi, D. K., Tieu, K., and Przedborski, S. (2001) The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 14, 483-489
14. O'Callaghan, J. P. (1993) Quantitative features of reactive gliosis following toxicant-induced damage of the CNS. Ann. N.Y. Acad. Sci. 679, 195-210
15. O'Callaghan, J. P., Jensen, K. F., and Miller, D. B. (1995) Quantitative aspects of drug and toxicant-induced astrogliosis. Neurochem. Int. 26, 115-124
16. Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., and O'Callaghan, J. P. (2002) Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16, 1474-1476
17. Sriram, K., Benkovic, S. A., Hebert, M. A., Miller, D. B., and O'Callaghan, J. P. (2004) Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: Key signaling pathway for astrogliosis in vivo? J. Biol. Chem. 279, 19936-19947
18. Hofman, F. M., Hinton, D. R., Johnson, K., and Merrill, J. E. (1989) Tumor necrosis factor in multiple sclerosis brain. J. Exp. Med. 170, 607-612
19. Lee, S. C., Liu, W., Dickson, D. W., Brosnan, C. F., and Berman, J. W. (1993) Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J. Immunol. 150, 2659-2667
20. Gregersen, R., Lambertsen, K., and Finsen, B. (2000) Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J. Cereb. Blood Flow Metab. 20, 53-65
21. Hunot, S., Hartmann, A., and Hirsch, E. C. (2001) The inflammatory response in the Parkinson brain. Clin. Neurosci. Res. 1, 434-443
22. Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., and Hashizume, Y. (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. (Berlin) 106, 518-526
23. Heikkila, R. E., Hess, A., and Duvoisin, R. C. (1985) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity. Life Sci. 36, 231-236
24. Perry, T. L., Yong, V. W., Jones, K., Wall, R. A., Clavier, R. M., Foulks, J. G., and Wright, J. M. (1985) Effects of N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse. Neurosci. Lett. 58, 321-326
25. Reinhard, J. F., Jr., Miller, D. B., and O'Callaghan, J. P. (1988) The neurotoxicant MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) increases glial fibrillary acidic protein and decreases dopamine levels of the mouse striatum: evidence for glial response to injury. Neurosci. Lett. 95, 246-251
26. Schneider, J. S., and Denaro, F. J. (1988) Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. J. Neuropathol. Exp. Neurol. 47, 452-458
27. O'Callaghan, J. P., Miller, D. B., and Reinhard, J. F., Jr. (1990) Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. 521, 73-80
28. Bezard, E., Dovero, S., Bioulac, B., and Gross, C. (1997) Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp. Neurol. 148, 288-292
29. Bruce, A. J., Boling, W., Kindy, M. S., Peschon, J., Kraener, P. J., Carpenter, M. K., Holtsberg, F. W., and Mattson, M. P. (1996) Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 2, 788-794
30. Gary, D. S., Bruce-Keller, A. J., Kindy, M. S., and Mattson, M. P. (1998) Ischemic and excitotoxic brain injury is enhanced in mice lacking the p55 tumor necrosis factor receptor. J. Cereb. Blood Flow Metab. 18, 1283-1287
31. O'Callaghan, J. P., and Sriram, K. (2004) Focused microwave irradiation of the brain preserves in vivo protein phosphorylation: comparison with other methods of sacrifice and analysis of multiple phosphoproteins. J. Neurosci. Methods 135, 159-168
32. Borit, A., Rubinstein, L. J., and Urich, H. (1975) The striatonigral degenerations. Putaminal pigments and nosology. Brain 98, 101-112
33. Bradbury, A. J., Costall, B., Jenner, P. G., Kelly, M. E., Marsden, C. D., and Naylor, R. J. (1986) MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal area. Neuropharmacology 25, 939-941
34. Ichitani, Y., Okamura, H., Matsumoto, Y., Nagatsu, I., and Ibata, Y. (1991) Degeneration of the nigral dopamine neurons after 6-hydroxydopamine injection into the rat striatum. Brain Res. 549, 350-353
35. Sauer, H., and Oertel, W. H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59, 401-415
36. Calabresi, P., Centonze, D., and Bernardi, G. (2000) Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci. 10, S57-S63
37. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85
38. O'Callaghan, J. P., Imai, H., Miller, D. B., and Minter, A. (1999) Quantitative immunoblots of proteins from brain homogenates: underestimation of specific protein concentration and of treatment effects. Anal. Biochem. 274, 18-26
39. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227, 680-685
40. Towbin, H., Staehelin, T., and Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76, 4350-4354
41. Schmued, L. C., and Hopkins, K. J. (2000) Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 874, 123-130
42. O'Callaghan, J. P., Martin, P. M., and Mass, M. J. (1998) The MAP kinase cascade is activated prior to the induction of gliosis in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of dopaminergic neurotoxicity. Ann. N. Y. Acad. Sci. 844, 40-49
43. Francis, J. W., Von Visger, J., Markelonis, G. J., and Oh, T. H. (1995) Neuroglial responses to the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine in mouse striatum. Neurotoxicol. Teratol. 17, 7-12
44. Benkovic, S. A., O'Callaghan, J. P., and Miller, D. B. (2004) Sensitive indicators of injury reveal hippocampal damage in C57BL/6J mice treated with kainic acid in the absence of tonic-clonic seizures. Brain Res. 1024, 59-76
45. Kreutzberg, G. W. (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19, 312-318
46. Streit, W. J., Walter, S. A., and Pennell, N. A. (1999) Reactive microgliosis. Prog. Neurobiol. 57, 563-581
47. Streit, W. J. (2000) Microglial response to brain injury: a brief synopsis. Toxicol. Pathol. 28, 28-30
48. Jonsson, G., Sundstrom, E., Mefford, I., Olson, L., Johnson, S., Freedman, R., and Hoffer, B. (1985) Electrophysiological and neurochemical correlates of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. Naunyn Schmiedebergs Arch. Pharmacol. 331, 1-6
49. Miller, D. B., Reinhard, J. F., Jr., Daniels, A. J., and O'Callaghan, J. P. (1991) Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium. J. Neurochem. 57, 541-549
50. Takada, M., Sugimoto, T., and Hattori, T. (1993) MPTP neurotoxicity to cerebellar Purkinje cells in mice. Neurosci. Lett. 150, 49-52
51. Freyaldenhoven, T. E., Ali, S. F., and Schmeud, L. C. (1997) Systemic administration of MPTP induces thalamic neuronal degeneration in mice. Brain Res. 759, 9-17
52. Shen, Y. Q., Hebert, G., Lin, L. Y., Luo, Y. L., Moze, E., Li, K. S., and Neveu, P. J. (2005) Interleukine-1beta and interleukin-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization. J. Neuroimmunol. 158, 14-25
53. Little, A. R., Benkovic, S. A., Miller, D. B., and O'Callaghan, J. P. (2002) Chemically induced neuronal damage and gliosis: Enhanced expression of the proinflammatory chemokine, monocyte chemoattractant protein (MCP)-1, without a corresponding increase in proinflammatory cytokines. Neuroscience 115, 307-320
54. Rousselet, E., Callebert, J., Parain, K., Joubert, C., Hunot, S., Hartmann, A., Jacque, C., Perez-Diaz, F., Cohen-Salmon, C., Launay, J. M., et al. (2002) Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp. Neurol. 177, 183-192
55. Leng, A., Mura, A., Feldon, J., and Ferger, B. (2005) Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease. Neurosci. Lett. 375, 107-111
56. Ferger, B., Leng, A., Mura, A., Hengerer, B., and Feldon, J. (2004) Genetic ablation of tumor necrosis factor-alpha (TNFalpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem. 89, 822-833
57. Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L., et al. (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 98, 14669-14674
58. Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D. K., Ischiropoulos, H., and Przedborski, S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763-1771
59. Yang, L., Sugama, S., Chirichigno, J. W., Gregorio, J., Lorenzl, S., Shin, D. H., Browne, S. E., Shimizu, Y., Joh, T. H., Beal, M. F., et al. (2003) Minocycline enhances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res. 74, 278-285
60. Sriram, K., Miller, D. B., and O'Callaghan, J. P. (2006) Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-α. J. Neurochem. 96, 706-718
61. Galasso, J. M., Wang, P., Martin, D., and Silverstein, F. S. (2000) Inhibition of TNF-alpha can attenuate or exacerbate excitotoxic injury in neonatal rat brain. Neuroreport 11, 231-235
62. Lawson, L. J., Perry, V. H., Dri, P., and Gordon, S. (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39, 151-170
63. Ren, L., Lubrich, B., Biber, K., and Gebicke-Haerter, P. J. (1999) Differential expression of inflammatory mediators in rat microglia cultured from different brain regions. Brain Res. Mol. Brain Res. 65, 198-205
64. Martin, P. M., and O'Callaghan, J. P. (1995) A direct comparison of GFAP immunocytochemistry and GFAP concentration in various regions of ethanol-fixed rat and mouse brain. J. Neurosci. Methods 58, 181-192
65. Cheng, B., Christakos, S., and Mattson, M. P. (1994) Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 12, 139-153
66. Mattson, M. P., Cheng, B., Baldwin, S. A., Smith-Swintosky, V. L., Keller, J., Geddes, J. W., Scheff, S. W., and Chrostakos, S. (1995) Brain injury and tumor necrosis factors induce calbindin D-28k in astrocytes: evidence for a cytoprotective response. J. Neurosci. Res. 42, 357-370
67. Uno, H., Matsuyama, T., Akita, H., Nishimura, H., and Sugita, M. (1997) Induction of tumor necrosis factor-alpha in the mouse hippocampus following transient forebrain ischemia. J. Cereb. Blood Flow Metab. 17, 491-499
68. Barger, S. W., Horster, D., Furukawa, K., Goodman, Y., Krieglstein, J., and Mattson, M. P. (1995) Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc. Natl. Acad. Sci. USA 92, 9328-9332
69. Kaltschmidt, B., Uherek, M., Wellmann, H., Volk, B., and Kaltschmidt, C. (1999) Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis. Proc. Natl. Acad. Sci. USA 96, 9409-9414
70. Albensi, B. C., and Mattson, M. P. (2000) Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 35, 151-159
71. Botchkina, G. I., Geimonen, E., Bilof, M. L., Villarreal, O., and Tracey, K. J. (1999) Loss of NF-kappaB activity during cerebral ischemia and TNF cytotoxicity. Mol. Med. 5, 372-381
72. Joseph, S. A., Tassorelli, C., Prasad, A. V., and Lynd-Balta, E. (1996) NF-kappa B transcription factor subunits in rat brain: colocalization of p65 and alpha-MSH. Peptides 17, 655-664
73. Teismann, P., Schwaninger, M., Weih, F., and Ferger, B. (2001) Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease. Neuroreport 12, 1049-1053
74. Tamatani, M., Che, Y. H., Matsuzaki, H., Ogawa, S., Okado, H., Miyake, S., Mizuno, T., and Tohyama, M. (1999) Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J. Biol. Chem. 274, 8531-8538
75. Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P., and Marsden, C. D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389
76. Sofic, E., Lange, K. W., Jellinger, K., and Riederer, P. (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142, 128-130
77. Sriram, K., Pai, K. S., Boyd, M. R., and Ravindranath, V. (1997) Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res. 749, 44-52
78. Pennathur, S., Jackson-Lewis, V., Przedborski, S., and Heinecke, J. W. (1999) Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J. Biol. Chem. 274, 34621-34628
79. Imam, S. Z., Newport, G. D., Itzhak, Y., Cadet, J. L., Islam, F., Slikker, W., Jr., and Ali, S. F. (2001) Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J. Neurochem. 76, 745-749